RNAa (RNA activation) is a platform technology to selectively turn genes on by using short duplex RNA known as small activating RNA (saRNA).
RNAa is one of the few technologies that can stimulate production of endogenous targeted genes.
The Push for the Next
Generation of Therapeutics
Ractigen has a diverse pipeline covering previously undruggable diseases and monogenic disorders including oncology, CNS, and liver-related indications.
The pipeline explores the boundaries of our technology and pushes for the next generation of RNAa therapeutics.
Meet Our Team
We are led by a cohesive team of scientists and professionals with a broad background in RNA research and drug development including the inventors of RNAa technology, nucleic acid chemists, biotech entrepreneurs and experts in drug discovery.
Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital
Ractigen Therapeutics, a leading company in the saRNA drug space…